Image by James Weaver
The US Food and Drug Administration (FDA) has granted 501(k) clearance for the Hemogrip Patch, a product used to treat uncontrolled hemorrhage.
The patch is designed to control bleeding that occurs when accessing veins or arteries for various medical treatments and applications.
The Hemogrip platform technology is based on chitosan, a natural biopolymer found in the exoskeleton of crustaceans.
Chitosan is biocompatible, anti-microbial, and durable under a range of environmental conditions.
When applied to wounds, Hemogrip creates a nano-scale, 3-dimensional mesh, rapidly coagulating blood and stopping blood loss.
Hemogrip technology has proven effective in a study of swine, halting uncontrolled hemorrhage in a model of lethal arterial injury. Other in vivo research showed that Hemogrip’s hemostatic effects are reversible.
The Hemogrip Patch is under development by the medical device company Remedium Technologies, a spin-out of the University of Maryland.
